Skip to main content
Top
Published in:

Open Access 09-05-2024 | Semaglutide | Brief Report

Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study

Authors: David M. Williams, Barbara-Alex Alberts, Asem Sharaf, Giselle Sharaf, Stephen C. Bain, Atul Kalhan, Thinzar Min

Published in: Diabetes Therapy | Issue 7/2024

Login to get access

Abstract

Introduction

Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.

Methods

People with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide.

Results

Seventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort.

Conclusions

Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group.
Literature
1.
go back to reference Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62.CrossRefPubMed Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62.CrossRefPubMed
2.
go back to reference Williams DM, Atkinson M, Evans M. Stroke prevention and treatment in people with type 2 diabetes: is there a role for GLP-1 (glucagon-like peptide-1) analogues? Stroke. 2023;54:1441–51.CrossRefPubMed Williams DM, Atkinson M, Evans M. Stroke prevention and treatment in people with type 2 diabetes: is there a role for GLP-1 (glucagon-like peptide-1) analogues? Stroke. 2023;54:1441–51.CrossRefPubMed
3.
go back to reference Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.CrossRefPubMed Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.CrossRefPubMed
4.
go back to reference Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.CrossRefPubMed Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.CrossRefPubMed
5.
go back to reference Iacobucci G. Diabetes: doctors are told not to start new patients on GLP-1 agonists because of shortages. BMJ. 2023;382:2019.CrossRefPubMed Iacobucci G. Diabetes: doctors are told not to start new patients on GLP-1 agonists because of shortages. BMJ. 2023;382:2019.CrossRefPubMed
6.
go back to reference Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.CrossRefPubMed Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.CrossRefPubMed
7.
go back to reference Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.CrossRefPubMed Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.CrossRefPubMed
8.
go back to reference McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25:1932–41.CrossRefPubMed McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25:1932–41.CrossRefPubMed
9.
go back to reference Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38:2041–51.CrossRefPubMedPubMedCentral Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38:2041–51.CrossRefPubMedPubMedCentral
10.
go back to reference Ruan Z, Jiang Y, Shi H, et al. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. Expert Rev Clin Pharmacol. 2023;16:161–76.CrossRefPubMed Ruan Z, Jiang Y, Shi H, et al. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. Expert Rev Clin Pharmacol. 2023;16:161–76.CrossRefPubMed
11.
go back to reference Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12:801–11.CrossRefPubMedPubMedCentral Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12:801–11.CrossRefPubMedPubMedCentral
12.
go back to reference Vilsbøll T, Lindahl CØ, Nielsen NF, Tikkanen CK. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25:1740–9.CrossRefPubMed Vilsbøll T, Lindahl CØ, Nielsen NF, Tikkanen CK. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25:1740–9.CrossRefPubMed
13.
go back to reference Ghusn W, Fansa S, Anazco D, et al. Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. Int J Obes (Lond). 2024;48:662–667.CrossRefPubMed Ghusn W, Fansa S, Anazco D, et al. Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. Int J Obes (Lond). 2024;48:662–667.CrossRefPubMed
14.
go back to reference Candido R, Gaiotti S, Giudici F, et al. Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes. J Clin Med. 2023;12:6052.CrossRefPubMedPubMedCentral Candido R, Gaiotti S, Giudici F, et al. Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes. J Clin Med. 2023;12:6052.CrossRefPubMedPubMedCentral
15.
go back to reference Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021;23:2177–82.CrossRefPubMedPubMedCentral Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021;23:2177–82.CrossRefPubMedPubMedCentral
16.
go back to reference Moreno-Pérez O, Reyes-Garcia R, Modrego-Pardo I, et al. Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: a nationwide multicentre retrospective observational study (ENDO2 S-RWD). Diabetes Obes Metab. 2024;26:1519–1523.CrossRefPubMed Moreno-Pérez O, Reyes-Garcia R, Modrego-Pardo I, et al. Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: a nationwide multicentre retrospective observational study (ENDO2 S-RWD). Diabetes Obes Metab. 2024;26:1519–1523.CrossRefPubMed
17.
go back to reference Kick A, M'Rabet-Bensalah K, Acquistapace F, et al. Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland Multicentre, Prospective, Observational Study. Diabetes Ther. 2024;15:623–637CrossRefPubMedPubMedCentral Kick A, M'Rabet-Bensalah K, Acquistapace F, et al. Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland Multicentre, Prospective, Observational Study. Diabetes Ther. 2024;15:623–637CrossRefPubMedPubMedCentral
18.
go back to reference Roy Chowdhury S, Sadouki F, Collins E, et al. Real-world use of oral and subcutaneous semaglutide in routine clinical practice in the UK: a single-centre, retrospective observational study. Diabetes Ther. 2024;15:869–881CrossRefPubMedPubMedCentral Roy Chowdhury S, Sadouki F, Collins E, et al. Real-world use of oral and subcutaneous semaglutide in routine clinical practice in the UK: a single-centre, retrospective observational study. Diabetes Ther. 2024;15:869–881CrossRefPubMedPubMedCentral
19.
go back to reference Fadini GP, Bonora BM, Ghiani M, et al. Oral or injectable semaglutide for the management of type 2 diabetes in routine care: a multicentre observational study comparing matched cohorts. Diabetes Obes Metab. 2024 [online ahead of print]. Fadini GP, Bonora BM, Ghiani M, et al. Oral or injectable semaglutide for the management of type 2 diabetes in routine care: a multicentre observational study comparing matched cohorts. Diabetes Obes Metab. 2024 [online ahead of print].
20.
go back to reference Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis. Diabetes Ther. 2021;12:1325–39.CrossRefPubMedPubMedCentral Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis. Diabetes Ther. 2021;12:1325–39.CrossRefPubMedPubMedCentral
Metadata
Title
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
Authors
David M. Williams
Barbara-Alex Alberts
Asem Sharaf
Giselle Sharaf
Stephen C. Bain
Atul Kalhan
Thinzar Min
Publication date
09-05-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 7/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01590-x

Other articles of this Issue 7/2024

Diabetes Therapy 7/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare